After the GSK share price leaps 21% in 4 months, I’m thinking about selling

Since its late-February low, the GSK share price has jumped more than a fifth. Four months on, is it time for me to sell up to seek higher returns?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve been a shareholder in pharmaceutical giant GlaxoSmithKline (LSE: GSK) since the late 1980s. Alas, over three decades, the GSK share price has been a serial disappointment. After surging to record highs in the previous millennium, the shares then struggled for years. And just when they seemed to be strengthening again, Covid-19 crashed markets and sent the stock steeply south once more.

The GSK share price’s rise and fall

At its record peak in 1999, the share price briefly topped £23. I know a GSK lifer who sold her entire holding at these elevated prices! But this peak didn’t last and the stock crashed back down during the 2000-03 market crash. The shares then bumped along for years, but rose to close at 1,846p on 17 January 2020. Then coronavirus ravaged the world and stocks went into meltdown.

Despite GSK being the world’s #1 vaccine maker, the GSK share price has been volatile in the past 16 months. It plunged in March 2020, but rebounded to end 2020 at 1,342p. Then price weakness resumed, with the shares falling to a fresh low of 1,190.8p on 26 February. However, over the past four months or so, the shares have staged a solid comeback. On Wednesday, they closed at 1,434.58p, up almost 245p from their 2021 low. That’s a leap of more than a fifth (20.5%) in 130 days. Not bad at all and most welcome, but what next?

GSK has been a poor long-term performer

The GSK share price is ahead 6.1% over one month, 1.9% over six months and 6.9% in 2021. Then again, it has dropped by 10.6% over one year and 13.2% over five years. Hardly the sort of performance I’d like to see as a long-term holder. Also, as GSK is the largest single stock in my family portfolio, its price has a significant impact on our wealth.

Nevertheless, the reason why I stick with GSK is very simple. For more than five years, the company has paid a yearly cash dividend of 80p a share. Based on the current GSK share price, that’s a market-beating dividend yield of nearly 5.6% a year. These cash payouts provide hefty passive income for our family portfolio. This is largely why we’ve stuck with the shares for so long. But all this is set to change in 2022, when GSK will break up into two separate companies. At this point, the £72.2bn company’s dividend will be slashed to 55p. Thereafter, the combined yearly dividend from New GSK and New Consumer Healthcare should exceed 45p. Alas, these two dividend cuts undermine my personal case for holding on to the stock in future.

Right now, the GSK share price stands at a discount of 14.1% to its 52-week high of 1,669.8p on 20 July 2020. It trades on a price-to-earnings ratio of 13.7 and an earnings yield of 7.3%. That isn’t expensive in historical terms, but GSK’s sales are expected to decline for a couple of years ahead. 

I feel I need to reduce our future exposure to the GSK share price, even though its plans could yield rich rewards one day. I’d think about selling in any decent price surges in 2021/22. Ideally, I’d like to exit at levels well above £15, but who knows when that might actually happen? Not me, that’s for sure. Finally, would I buy this FTSE 100 stock today if I didn’t already own it? I’m not sure that I would, to be fair.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Cliffdarcy owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Long-term vs short-term investing concept on a staircase
Investing Articles

Should investors rush to buy Aviva shares before the end of the year?

The 7.5% dividend yield on Aviva shares is attractive. But Stephen Wright thinks a different FTSE 100 insurer is a…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

2 UK stocks for value investors to consider buying before the end of the year

Exploiting cyclical downturns can be a great way for value investors to find stocks to buy at bargain prices. Stephen…

Read more »

Young woman holding up three fingers
Investing Articles

I’d earn £1,260 in passive income by investing a £20k Isa in these 3 ultra-high-yield stocks

I'm on the hunt for passive income and I reckon the following FTSE 100 stocks should help me generate it…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Could these beleaguered FTSE 100 stocks stage a turnaround?

Could these FTSE 100 stocks be primed for recovery after difficult times? Sumayya Mansoor takes a look at what could…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

Is this FTSE 100 giant one of the best income stocks out there?

Our writer takes a closer look at this medical business as a potential income stock for her portfolio, even though…

Read more »

Bournemouth at night with a fireworks display from the pier
Investing Articles

£2k in a Stocks and Shares ISA? One top stock I’d buy before the New Year!

Here's one US stock this writer thinks could grow for a long time to come and deliver attractive returns in…

Read more »

Front view photo of a woman using digital tablet in London
Investing Articles

How I’d invest £4k in my SIPP with the aim of doubling my money

Jon Smith talks through how he'd use dividend growth stocks to grow a SIPP pot consistently to achieve strong long-term…

Read more »

Stack of one pound coins falling over
Investing Articles

£3 a day vs £30 a day passive income plan

What’s the difference between a £3 a day and £30 a day passive income plan? More to the point, how…

Read more »